Table 1

Baseline characteristics

CharacteristicCS (800 mg/day)Placebo
(n=35)(n=34)p Value
Age (years)59.7 ± 9.464.9 ± 9.50.025
BMI (kg/m2)30.4 ± 4.631.5 ± 5.20.381
Women (n (%))21 (60.0)20 (58.8)>0.999
Cartilage volume (mm3)6347.1 ± 1815.56039.1 ± 1640.70.466
BML global score1.8 ± 2.12.2 ± 2.20.372
Knee swelling and effusion (n (%))19 (54.3)22 (64.7)0.465
Synovial membrane thickness (mm)1.8 ± 0.551.8 ± 0.630.855
WOMAC total (0–2400)1408.3 ± 357.31345.8 ± 430.50.513
VAS (0–100)63.0 ± 15.962.3 ± 17.60.856
SF-36 general health (0–100)70.3 ± 16.572.3 ± 16.70.617
  • Baseline characteristics for the double-blind cohort (n=69). Data are expressed as mean ± SD or number of subjects (%) when appropriate.

  • BMI, body mass index; BML, bone marrow lesion; CS, chondroitin sulphate; SF-36, Short Form 36 General Health questionnaire; VAS, visual analogue scale; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.